Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCR

A proposed class action settlement of $3,750,000 has been reached on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020, and March 19, 2024. The settlement requires court approval at a hearing scheduled for July 28, 2026. Class members must submit claim forms by July 7, 2026, to be eligible for distribution from the settlement fund.

04/06/2026, 8:00 AM • GlobeNewswire

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical announced it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. This is the company's third commercial site transfer since October 2025. The product is expected to generate commercial revenue within 24 months and contribute to Lifecore's targeted 2029 revenue CAGR of 12%. The agreement demonstrates successful execution of the company's strategy to secure lower-risk, late-stage programs with faster paths to commercial revenue.

03/23/2026, 7:00 AM • GlobeNewswire

Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP announced investigations into potential securities law violations by Green Dot Corporation, Lifecore Biomedical, and Horizon Technology Finance on behalf of affected investors. Green Dot's stock declined approximately 7% following the company's announcement of delayed financial results for Q4 and full year 2025.

03/16/2026, 8:02 PM • GlobeNewswire

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP announced investigations into three companies on March 16, 2026. Lifecore Biomedical issued disappointing 2026 revenue guidance of $120-125 million versus $141.4 million in 2025, citing customer loss and product launch delays, resulting in an 18% stock decline. The firm is also investigating Horizon Technology Finance and G-III Apparel Group for potential federal securities law violations.

03/16/2026, 5:56 PM • GlobeNewswire

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical's compensation committee approved equity inducement grants on January 14, 2026, awarding 1,738 RSUs and 8,775 stock options to two newly hired employees. The RSUs vest after three years, while stock options vest monthly over three years with a seven-year exercise term.

01/16/2026, 4:45 PM • GlobeNewswire

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Lifecore Biomedical has signed a master services agreement with a new large global pharmaceutical customer to conduct development services and tech transfer for an injectable pharmaceutical product, potentially becoming a top five commercial customer.

12/17/2025, 7:00 AM • GlobeNewswire

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Lifecore Biomedical will participate in three pharmaceutical industry conferences in October and November 2025, including PODD, CPHI Worldwide, and American Pharma Manufacturing & Outsourcing Summit, where they will host booth meetings and participate in panel discussions.

10/13/2025, 7:00 AM • GlobeNewswire

LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against LifeCore Biomedical for alleged false financial statements and internal control deficiencies during October 2020 to March 2024 period.

09/27/2025, 8:31 AM • GlobeNewswire

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against LifeCore Biomedical for alleged false financial statements and internal control deficiencies during October 2020 to March 2024 period.

08/14/2025, 8:42 PM • GlobeNewswire